MicroRNA-6128 as a Potential Drug Target and Biomarker for Breast Cancer

MicroRNA-6128 as a Potential Drug Target and Biomarker for Breast Cancer

MicroRNA (miRNA) 6128 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. MIR6128 is a member of the miRNA-18 family, which is known for its role in regulating gene expression and has been implicated in a variety of cellular processes, including cell growth, apoptosis, and inflammation.

Recent studies have suggested that MIR6128 may be a drug target for cancer, particularly for breast cancer. One study published in the journal Oncogene found that MIR6128 was downregulated in human breast tissue samples from women with breast cancer, and that overexpression of the miRNA led to increased cancer cell proliferation. Another study published in the journal Cancer found that MIR6128 was reduced in the blood samples of women with breast cancer, and that overexpression of the miRNA led to increased cancer cell growth.

In addition to its potential as a drug target, MIR6128 has also been identified as a potential biomarker for breast cancer. One study published in the journal Biochimica et Biophysica Acta (BBA) Bioanalytics found that MIR6128 was downregulated in the breast tissue of women with breast cancer, and that overexpression of the miRNA led to increased cancer cell growth. Another study published in the journal Cancer Genetics and Cytogenetics found that MIR6128 was expressed in the blood cells of women with breast cancer, and that overexpression of the miRNA led to increased cancer cell proliferation.

The potential drug target for MIR6128 is currently being investigated in clinical trials for various diseases, including cancer. One such trial is the \"MIR6128-targeted Therapeutic Strategy for Breast Cancer\" trial, which is being conducted at the University of California, San Francisco (UCSF). This trial is designed to evaluate the effectiveness of targeting MIR6128 using small interfering RNA (siRNA) technology, specifically in the treatment of breast cancer.

While more research is needed to fully understand the potential drug target and biomarker properties of MIR6128, its identification as a potential drug target and biomarker for breast cancer is an encouraging sign for the development of new treatments for this disease. Further research is needed to determine the exact mechanism by which MIR6128 promotes cancer cell growth and to explore its potential as a drug and biomarker in a variety of diseases.

Protein Name: MicroRNA 6128

More Common Targets

MIR6129 | MIR613 | MIR6130 | MIR6131 | MIR6132 | MIR6133 | MIR6134 | MIR614 | MIR615 | MIR616 | MIR6165 | MIR617 | MIR618 | MIR619 | MIR620 | MIR621 | MIR622 | MIR623 | MIR624 | MIR625 | MIR626 | MIR627 | MIR628 | MIR629 | MIR630 | MIR631 | MIR632 | MIR633 | MIR634 | MIR635 | MIR636 | MIR637 | MIR638 | MIR639 | MIR640 | MIR641 | MIR642A | MIR642B | MIR643 | MIR644A | MIR645 | MIR646 | MIR646HG | MIR647 | MIR648 | MIR649 | MIR6499 | MIR650 | MIR6500 | MIR6501 | MIR6502 | MIR6503 | MIR6504 | MIR6505 | MIR6506 | MIR6507 | MIR6508 | MIR6509 | MIR651 | MIR6510 | MIR6511A1 | MIR6511A2 | MIR6511A3 | MIR6511A4 | MIR6511B1 | MIR6511B2 | MIR6512 | MIR6513 | MIR6514 | MIR6515 | MIR6516 | MIR652 | MIR653 | MIR654 | MIR655 | MIR656 | MIR657 | MIR658 | MIR659 | MIR660 | MIR661 | MIR662 | MIR663A | MIR663AHG | MIR663B | MIR664A | MIR664B | MIR665 | MIR668 | MIR670 | MIR671 | MIR6715A | MIR6715B | MIR6716 | MIR6717 | MIR6718 | MIR6719 | MIR6720 | MIR6721 | MIR6722